ホーム › 非小細胞肺癌 › オハイオ › Cincinnati
Cincinnati、OHにおける非小細胞肺癌の臨床試験
Cincinnatiとその周辺地域（約30マイル以内）の拠点で、非小細胞肺癌に関する35件の研究が参加者を募集しています。研究を開いて、参加資格と連絡方法を確認してください。
公式研究テキスト（英語）
ここで研究参加者を募集していますか？ このページの上部に表示できます — 30日間 $99 →
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
被験者募集中第3相
- University of Cincinnati Medical Center ( Site 0119), Cincinnati
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)
被験者募集中第3相
- The Christ Hospital, Cincinnati
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
被験者募集中第3相
- Local Institution - 0383, Cincinnati
Neladalkib (NVL-655) for TKI-naive Patients With Advanced ALK-Positive NSCLC
被験者募集中第3相
- University of Cincinnati Cancer Center, Cincinnati
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)
被験者募集中第3相
- TriHealth Cancer & Blood Institute Research, Cincinnati
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- Oncology_Hematology Care Clinical Trials,LLC, Cincinnati
- 他1件
A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)
被験者募集中第3相
- Saint Elizabeth Medical Center Edgewood-Cancer Care Center ( Site 0061), Edgewood · 8マイル先
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
被験者募集中第3相
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- Oncology Hematology Care Clinical Trials, Cincinnati
- 他1件
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2相
- Cincinnati Veterans Affairs Medical Center, Cincinnati
A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%
被験者募集中第3相
- University of Cincinnati Medical Center, Cincinnati
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8マイル先
Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations
被験者募集中第3相
- Research Site, Cincinnati
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
被験者募集中第2/3相
- The Christ Hospital Cancer Center, Cincinnati
- University of Cincinnati Medical Center, Cincinnati
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
被験者募集中第3相
- Saint Elizabeth Medical Center Edgewood, Edgewood · 8マイル先
A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)
被験者募集中第3相
- Research Site, Cincinnati
Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
被験者募集中第3相
- Clinical Study Sites, Cincinnati
Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7
被験者募集中第2/3相
- Local Institution - 007-893-B, Cincinnati
- USOR - Oncology Hematology Care - Blue Ash, Cincinnati
- Local Institution - 007-893-C, Cincinnati
- 他1件
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
被験者募集中第2/3相
- Oncology Hematology Care, Inc - Blue Ash /ID# 262733, Cincinnati
FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC
被験者募集中第1/2相
- Christ Hospital, Cincinnati
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
被験者募集中第3相
- University of Cincinnati Medical Center-University of Cincinnati Cancer Center ( Site 0103), Cincinnati
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
被験者募集中第3相
- USO - Oncology Hematology Care, Cincinnati
MOONRAY-01, A Study of LY3962673 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- University of Cincinnati (UC) - Cancer Institute, Cincinnati
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
被験者募集中第1相
- St. Elizabeth Healthcare, Edgewood · 8マイル先
Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In
被験者募集中第3相
- University of Cincinnati Medical Center, Cincinnati
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
被験者募集中第2相
- University of Cincinnati Medical Center, Cincinnati
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
被験者募集中第1/2相
- University of Cincinnati, Cincinnati
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
被験者募集中第1相
- The Christ Hospital, Cincinnati
MYLUNG Consortium Part 3: Observational Study
被験者募集中観察研究
- Oncology Hematology Care Clinical Trials, LLC, Cincinnati
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
被験者募集中第1/2相
- Christ Hospital Cancer Center, Cincinnati
Study of PF-07248144 in Advanced or Metastatic Solid Tumors
被験者募集中第2相
- St. Elizabeth Healthcare, Edgewood · 8マイル先
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Carl & Edyth Lindner Center for Research & Education at The Christ Hospital and The Christ Hospital Cancer Center, Cincinnati
Promoting Immunotherapy Efficacy With Low-Dose Liver RT
被験者募集中
- University of Cincinnati Medical Center, Cincinnati
GEMINI-NSCLC: NSCLC Biomarker Study
被験者募集中観察研究
- TriHealth Cancer Institute, Cincinnati
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
被験者募集中第1/2相
- Research Site 113, Cincinnati
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
被験者募集中観察研究
- Massive Bio SYNERGY-AI site, Cincinnati
A Study of Orally Administered JBI-802 Alone or in Combination With Pembrolizumab for Patients With Non-small Cell Lung Cancer With an STK11 Mutation.
被験者募集中第2相
- The Christ Hospital, Cincinnati
他の都市における非小細胞肺癌の試験
- Houston, TX145件の研究
- New York City, NY120件の研究
- Arlington, VA104件の研究
- Nashville, TN97件の研究
- Boston, MA90件の研究
- Los Angeles, CA87件の研究
- St. Louis, MO73件の研究
- Chicago, IL61件の研究
- Baltimore, MD60件の研究
- San Antonio, TX59件の研究
- Columbus, OH56件の研究
- Washington, DC55件の研究
Cincinnatiにおける他の研究
- がん（全種類）27件の研究
- 乳がん25件の研究
- 心不全24件の研究
- 大腸癌21件の研究
- 急性骨髄性白血病20件の研究
- 転移性癌20件の研究
- 卵巣がん19件の研究
- 肺がん19件の研究
- 肥満症19件の研究
- 前立腺がん18件の研究
- 多発性骨髄腫17件の研究
- 悪性黒色腫17件の研究
ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。